Evidence map›Paper›PMID 31593563›Full record

Trial reportPLoS neglected tropical diseases2019

Longitudinal evaluation of asymptomatic Leishmania infection in HIV-infected individuals in North-West Ethiopia: A pilot study.

Johan van Griensven, Saskia van Henten, Bewketu Mengesha, Mekibib Kassa, Emebet Adem, Mengistu Endris Seid, Saïd Abdellati, Wondimu Asefa, Tesfa Simegn, Degnachew Debasu and 8 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02839603 (Asymptomatic Leishmania Infection and Burden of Visceral Leishmaniasis in HIV-infected Individuals in North West Ethiopia), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02839603 terminatednot on this map

Asymptomatic Leishmania Infection and Burden of Visceral Leishmaniasis in HIV-infected Individuals in North West Ethiopia: a Pilot Study

TypeobservationalSponsorInstitute of Tropical Medicine, BelgiumRan2015 to 2017Enrolled540ConditionsVisceral Leishmaniasis
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Assessment of asymptomaticFrontiers in medicine · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Johan van GriensvenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-6581-2964
Saskia van HentenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bewketu MengeshaMedical College, University of Gondar, Gondar, Ethiopia.
Mekibib KassaMedical College, University of Gondar, Gondar, Ethiopia.
Emebet AdemMedical College, University of Gondar, Gondar, Ethiopia.
Mengistu Endris SeidMedical College, University of Gondar, Gondar, Ethiopia.ORCID 0000-0003-4417-2085
Saïd AbdellatiDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-9620-8257
Wondimu AsefaMedical services, Metema district hospital, Metema, Ethiopia.
Tesfa SimegnMedical services, Metema district hospital, Metema, Ethiopia.
Degnachew DebasuMedical services, Metema district hospital, Metema, Ethiopia.
Tadfe BogaleMedical College, University of Gondar, Gondar, Ethiopia.
Yonas GedamuMedical College, University of Gondar, Gondar, Ethiopia.ORCID 0000-0003-4109-6849
Dorien Van Den BosscheDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Wim AdriaensenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Gert Van der AuweraDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-3742-7046
Lieselotte CnopsDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Florian VogtDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Ermias DiroMedical College, University of Gondar, Gondar, Ethiopia.
Instituut voor Tropische Geneeskunde · BEUniversity of Gondar · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn endemic regions, asymptomatic Leishmania infection is common. In HIV patients, detection of asymptomatic Leishmania infection could potentially identify those at risk of visceral leishmaniasis (VL). However, data on the prevalence, incidence, and determinants of asymptomatic infection, and the risk of VL are lacking.

methodsWe conducted a cross-sectional survey at a single ART centre, followed by a prospective cohort study amongst HIV-infected adults in HIV care in a district hospital in a VL-endemic area in North-West Ethiopia (9/2015-8/2016). Asymptomatic Leishmania infection was detected using the direct agglutination test (DAT), rK39-rapid diagnostic test (RDT)), PCR on peripheral blood and the KAtex urine antigen test, and defined as positivity on any Leishmania marker. All individuals were followed longitudinally (irrespective of the Leishmania test results). Risk factors for asymptomatic Leishmania infection were determined using logistic regression.

resultsA total of 534 HIV-infected individuals enrolled in HIV care were included in the study. After excluding 13 patients with a history of VL and an 10 patients with incomplete baseline Leishmania tests, 511 were included in analysis. The median age was 38 years (interquartile range (IQR) 30-45), 62.6% were male. The median follow-up time was 12 months (IQR 9-12). No deaths were reported during the study period. Most (95.5%) were on antiretroviral treatment at enrolment, for a median of 52 months (IQR 27-79). The median CD4 count at enrolment was 377 cells/mm3 (IQR 250-518). The baseline prevalence of Leishmania infection was 12.8% in males and 4.2% in females. Overall, 7.4% tested positive for rK39, 4.3% for DAT, 0.2% for PCR and 0.2% for KAtex. Independent risk factors for a prevalent infection were male sex (odds ratio (OR) 3.2; 95% confidence intervals (CI) 14-7.0) and concurrent malaria infection (OR 6.1; 95% CI 1.9-18.9). Amongst the 49 prevalent (baseline) infections with further follow-up, the cumulative incidence of losing the Leishmania markers by one year was 40.1%. There were 36 incident infections during the course of the study, with a cumulative one-year risk of 9.5%. Only one case of VL was detected during follow-up.

conclusionsWe found a high prevalence of asymptomatic Leishmania infection, persisting in most cases. The incidence was more modest and overt VL was rare. Larger and longer studies with more complete follow-up may help to decide whether a test and treat strategy would be justified in this context.

trial registrationClinicalTrials.gov NCT02839603.

Indexed as

Asymptomatic InfectionsAdolescentAdultAgglutination TestsAnti-Retroviral AgentsCD4 Lymphocyte CountCross-Sectional StudiesDiagnostic Tests, RoutineEthiopiaFemaleHIV InfectionsHumansLeishmaniasisLeishmaniasis, VisceralLongitudinal StudiesMaleAnti-Retroviral Agents

Identifiers

PMID31593563
PMCPMC6799935
OpenAlexW2979432595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.